Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

8300	Companies
115005	Keywords
55382	Articles
62486	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 05/02/2024 at 07:30, 6 months 19 days ago

MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
Theranexus annonce le dépôt de son document d'enregistrement universel pour l'exercice 2023, disponible sur son site. Theranexus se spécialise dans le traitement des maladies neurologiques rares

Biopharmaceutique Theranexus Maladies Neurologiques Rares Dépôt Document D'enregistrement Universel Neurones Et Cellules Gliales
BRIEF

published on 04/29/2024 at 18:25, 6 months 21 days ago

Theranexus publie ses résultats annuels 2023 et détaille ses progrès récents

Résultats Financiers 2023 Theranexus Maladies Neurologiques Rares Maladie Des Lattes Projet PickASO
BRIEF

published on 04/29/2024 at 18:25, 6 months 21 days ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE

published on 04/29/2024 at 18:20, 6 months 21 days ago

THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials

Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF

published on 04/29/2024 at 18:05, 6 months 21 days ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF

published on 04/29/2024 at 18:05, 6 months 21 days ago

Theranexus annonce ses résultats annuels 2023 et les avancées de ses projets

Biotechnologie Résultats Financiers 2023 Maladies Rares Theranexus Phase De Recherche
PRESS RELEASE

published on 04/29/2024 at 18:00, 6 months 21 days ago

THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS
Theranexus, société biopharmaceutique à lyon, publie ses résultats annuels 2023, sa trésorerie 31 mars 2024 et ses activités. Nouvelle Directrice administrative et financière. Projets innovants dans maladies neurologiques rares

Résultats Annuels Trésorerie Theranexus Maladies Neurologiques Rares Christine Placet
BRIEF

published on 04/26/2024 at 18:05, 6 months 24 days ago

Theranexus publie ses informations sur les droits de vote et le capital pour mars 2024

Droits De Vote Capital Social Biopharmaceutique Theranexus Neurologie
BRIEF

published on 04/26/2024 at 18:05, 6 months 24 days ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
PRESS RELEASE

published on 04/26/2024 at 18:00, 6 months 24 days ago

Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital
Theranexus publie le nombre d'actions et de droits de vote au 31 mars 2024, renforçant sa transparence. Détails sur son engagement dans le traitement des maladies neurologiques rares

Droits De Vote Capital Social Biopharmaceutique Theranexus Maladies Neurologiques Rares

Accesswire

Published on 11/21/2024 at 15:05, 25 minutes ago

"The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 30 minutes ago

2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 30 minutes ago

Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 30 minutes ago

BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization
Published on 11/21/2024 at 15:00, 30 minutes ago

RE Royalties Enters into Loan and Royalty Agreement with Abraxas Power for up to CAD $10 Million and Announces Loan Settlement with Switch Power

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 15:24, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:19, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tritax EuroBox plc
Published on 11/21/2024 at 15:18, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc
Published on 11/21/2024 at 15:17, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc
Published on 11/21/2024 at 15:16, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Britvic plc

Les Echos

Published on 11/21/2024 at 06:58, 8 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 32 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 19 hours 23 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 10 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE